Anti-gp40 x Anti-TFRC Bispecific Antibody (IgG-IgG) (BSIG-164)

Anti-gp40 x Anti-TFRC Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-gp40 and anti-TFRC parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can bind two tumor antigens simultaneously. It is designed for the research of Colon cancer; Ovarian cancer therapy.

Datasheet INQUIRY

Specifications

Targets

gp40 & TFRC

Type

IgG-IgG

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Colon cancer; Ovarian cancer

Targets

Target 1

gp40

Alternative Names

gp40; glycoprotein 40; adenocarcinoma-associated antigen

Target 2

TFRC

Gene ID

7037

UniProt ID

P02786

Alternative Names

TFRC; transferrin receptor; T9; TR; TFR; p90; CD71; TFR1; TRFR; transferrin receptor protein 1; transferrin receptor (p90, CD71); IMD46

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-gp40 x Anti-TFRC Bispecific Antibody (IgG-IgG) (BSIG-164). Click the button below to contact us or submit your feedback about this product.

Anti-gp40 x Anti-TFRC Bispecific Antibody (IgG-IgG) (CAT#: BSIG-164)

Specifications

Targets

Customer Reviews and Q&As